Use of anti-hypertensive medications and post-transplant renal allograft function in children.
Post-transplant hypertension is a common occurrence in children. The relative effect of this hypertension on renal allograft function is uncertain. Examining the accumulated data for pediatric renal transplant recipients at our institution from monthly visits for up to three years, we determined whether the use of anti-hypertensive medications (anti-HTN medications) was associated with allograft dysfunction. Monthly clinical data included height, weight, serum creatinine, cyclosporin A (CsA) trough levels, number of acute rejection episodes, and number of anti-HTN medications. Estimated glomerular filtration rate (eGFR) was calculated monthly for each patient using the Schwartz formula. Time post-transplant was grouped into 6-month intervals. One thousand three hundred and sixty-three monthly data sets from 6 months (n = 76 patients) to 3 yr post-transplant (n = 47 patients) were analyzed. Overall mean eGFR was 75 mL/min/1.73 m2 at 6 months and 54 mL/min/1.73 m2 at 3 yr. A lower eGFR was found at all post-transplant time intervals for patients receiving anti-HTN medications compared with those who were not (p < 0.01). This lower eGFR was found at some but not all times post-transplant when patients were grouped by donor type or history of acute rejection episodes and analyzed separately. Mean CsA trough levels were higher at all post-transplant time intervals in patients receiving anti-HTN medications (p < 0.05). While a causal relationship between post-transplant hypertension and graft dysfunction cannot be established from this study, we conclude that the need for anti-HTN medications is associated with worse allograft function.
Sorof
J M
JM
Department of Pediatrics, Baylor University School of Medicine, Houston, Texas, USA.
Goldstein
S L
SL
Brewer
E D
ED
Steiger
H M
HM
Portman
R J
RJ
D000208:Acute Disease; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002102:Cadaver; D002648:Child; D016572:Cyclosporine / Q000627:therapeutic use; D005919:Glomerular Filtration Rate; D006084:Graft Rejection; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000209:etiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000502:physiology; D019520:Living Donors
D000959:Antihypertensive Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine